SCHEMBL15325979

SCHEMBL15325979

COC(=O)c1ccc(-c2nc(CS[C@H]3CC[C@@H](NC(=O)OC(C)(C)C)CC3)c(C)o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
HRH1 P35367 1/20 0.46
MEN1 O00255 2/20 0.45
TP53 P04637 2/20 0.44
ALDH1A1 P00352 1/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15325935 1.00 KMT2A (0.49) KMT2AHRH1MEN1TP53ALDH1A1
SCHEMBL12469084 1.00 KMT2A (0.49) KMT2AHRH1MEN1TP53ALDH1A1
SCHEMBL15325998 0.95 KMT2A (0.45) KMT2AHRH1MEN1TP53ALDH1A1
SCHEMBL15325993 0.95 KMT2A (0.45) KMT2AHRH1MEN1TP53ALDH1A1
SCHEMBL12471457 0.86 KMT2A (0.45) KMT2AMEN1TP53ALDH1A1HSD17B10
SCHEMBL15325934 0.85 KMT2A (0.47) KMT2AHRH1MEN1TP53USP2
SCHEMBL15325984 0.85 KMT2A (0.47) KMT2AHRH1MEN1TP53USP2
SCHEMBL12469068 0.85 KMT2A (0.47) KMT2AHRH1MEN1TP53USP2
SCHEMBL12468730 0.84 KMT2A (0.49) KMT2AHRH1MEN1ALDH1A1USP2
SCHEMBL12468923 0.84 KMT2A (0.51) KMT2AHRH1MEN1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 US disclosed
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 US disclosed
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES ARAVIVE BIOLOGICS, INC. 2015-03-12 US disclosed
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES ARAVIVE BIOLOGICS, INC. 2015-03-12 US disclosed
US-20140024649-A1 Substituted Benzamides and Their Uses AUCKLAND UNISERVICES LIMITED (NZ) 2014-01-23 US disclosed
US-20140024649-A1 Substituted Benzamides and Their Uses AUCKLAND UNISERVICES LIMITED (NZ) 2014-01-23 US disclosed
WO-2013155338-A2 SUBSTITUTED BENZAMIDES AND THEIR USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA KMT2A 459/4885HRH1 1281/4885MEN1 2797/4885
US-20140024649-A1 Substituted Benzamides and Their Uses NISCH, BTD, NAAA KMT2A 459/4885HRH1 1281/4885MEN1 2797/4885
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA KMT2A 459/4885HRH1 1281/4885MEN1 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.